DBcare is a herbal food supplement that has been used over the years in India as a "traditional"anti-diabetic formula.DBcare was not tested controlled trials in humans, yet.We intend to test the ability of DBCare to improve blood sugar level control in patients with uncontrolled diabetes.
Study design: prospective, randomized, single-blind, placebo-controlled trial Inclusion criteria: Men and women (older than 18 years old) with type 2 diabetes and inadequate glycemic control, defined by HbA1C 8% ³ £10%. Previous medications include any oral hypoglycemic agents, as monotherapy or in combination. Concurrent lipid-lowering, anti-hypertensive and other medications are allowed Exclusion criteria (before the study): Type 1 diabetes mellitus Pregnant or lactating women Insulin treatment 3 months prior to study entry Creatinine \>2 mg/dL Abnormal liver function tests GOT\>X2 or GPT\>X2 the upper normal limit Unstable anginal syndrome Congestive heart failure (NYHA class I-IV) Inability to follow study instructions including low compliance Exclusion criteria (during the study): Severe hypoglycemia (less than 50 mg%) or any hypoglycemic event requiring intravenous glucose infusion Number of patients: 30 patients (drug) 30 patients (placebo) Design: Four out-patient visits, at enrollment and every month thereafter At enrollment (visit 1) physical examination will be performed and a full set of blood tests will be withdrawn At 1 week (visit 2) adjustment of hypoglycemic medications will be done and full chemistry and blood count will be taken At 6 weeks (visit 3) adjustment of hypoglycemic medications will be done and full chemistry and blood count will be taken At 12 weeks (visit 4), the end of the study, physical examination will be performed and a full set of blood tests will be withdrawn On the 2nd 3rd and 4th visits pill-count will be performed Glucose monitoring: patients will be asked to monitor fasting glucose levels at home, in the morning, on a daily basis Drugs: identical drug containing/ placebo capsules Drugs for a month will be given in each monthly visit Dose: 2 tablets three times daily
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
35
Meir Medical Center
Kfar Saba, Israel
Reduction of more than 0.5% GBA1C in the treatment group compared to placebo
Time frame: 3 months
Reduction in fasting plasma glucose of more than 20% in the treatment group compared to placebo
Time frame: 3 months
Reduction by half in the daily dose of oral hypoglycemic agents compared to baseline
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.